Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Exciting CAR-T clinical trials in LBCL and FL

Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, outlines some exciting ongoing clinical trials investigating CAR T-cell products in lymphoma. The ZUMA-23 trial (NCT05371093) is a Phase III trial of axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) regimens in the first-line for patients with high-risk large B-cell lymphoma (LBCL). In the setting of follicular lymphoma (FL), ZUMA-22 (NCT05371093) and LEDA (NCT05888493) are comparing axi-cel and tisagenlecleucel (tisa-cel), respectively, to SOC chemoimmunotherapy regimens. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Honoraria and travel support: Novartis, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Autolus, Sandoz, Miltenyi, AstraZeneca.